Good Therapeutics, a brand new Seattle biotech startup that goals to develop protein medicine that act solely when wanted, raised $11 million in fairness spherical looking for twice that quantity, based on a brand new SEC submitting.
The secretive startup is making an attempt to “make safer, more practical medication that acts solely when and the place they’re wanted, limiting systemic toxicity without lowering therapeutic efficacy,” based on its web site. Good mentioned it’s growing an algorithm that can design proteins for most cancers therapies. Founder and CEO John Mulligan sanctioned the $11 million spherical however declined to touch upon what it means for the corporate when contacted by GeekWire.
Mulligan, who received his doctorate in biology from Stanford College, beforehand labored as a guide for Microsoft on a system for storing information on strands of DNA, in response to his LinkedIn. He additionally based Glycostasis, an organization that designed a protein to manage insulin ranges, and Co-based Cambrian Genomics, which created an option to laser print DNA. Good’s places of work are in Seattle’s Fremont neighborhood, in keeping with the submitting.